Found: 8
Select item for more details and to access through your institution.
Ivacaftor in People With Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation.
- Published in:
- Annals of the American Thoracic Society, 2021, v. 18, n. 3, p. E1, doi. 10.1513/annalsats.202006-659oc
- By:
- Publication type:
- Article
Ivacaftor in People with Cystic Fibrosis and a → or Residual Function Mutation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 1, p. 46, doi. 10.1002/art.39473
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 2, p. 334, doi. 10.1002/art.38949
- By:
- Publication type:
- Article
Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization.
- Published in:
- Pulmonary Therapy, 2021, v. 7, n. 2, p. 455, doi. 10.1007/s41030-021-00158-5
- By:
- Publication type:
- Article
Attenuated liver fibrosis after bile duct ligation and defective hepatic stellate cell activation in neural cell adhesion molecule knockout mice.
- Published in:
- Liver International, 2011, v. 31, n. 5, p. 630, doi. 10.1111/j.1478-3231.2011.02486.x
- By:
- Publication type:
- Article